Select a State

Global health R&D delivers for Missouri

US government investment in global health R&D has delivered

$73.6 million
to Missouri research institutions
850+ new jobs
for Missouri

Neglected diseases in Missouri

Chikungunya cases
24
Dengue cases
35
HIV diagnoses
4,599
Malaria cases
118
Tuberculosis cases
855
West Nile cases
135
Zika cases
38

Missouri's top USG-funded global health R&D institutions

Washington University
$60.8 million
Saint Louis University
$7.4 million
University of Missouri-Kansas City
$3.6 million
University of Missouri-Columbia
$1.8 million
University of Missouri-St. Louis
$81 thousand

Missouri industry in global health R&D

Bayer
Location(s):
Kansas City
Charles River Laboratories
Location(s):
O’Fallon
Mediomics
Location(s):
St. Louis
Pfizer
Location(s):
St. Louis
Sanofi
Location(s):
St. Louis

Missouri's top areas of global health R&D by USG funding

3.0%
HIV/AIDS
19.0%
Malaria
13.5%
Tuberculosis
2.7%
Diarrheal diseases
6.2%
Salmonella infections
44.6%
Neglected tropical diseases
Dengue
Helminths
Kinetoplastids
11.0%
Other
Bacteria pneumonia & meningitis
Cryptococcal meningitis
Ebola/viral hemorrhagic fevers
Non-allocable

Global health R&D at work in Missouri

Researchers from Washington University School of Medicine have discovered that the Zika virus uses the process of autophagy, or cellular waste disposal—a key feature of the placental barrier—to infect the fetus. Their research also showed that an existing malaria drug, hydroxychloroquine, can protect the fetus by blocking this process. The drug is already approved for short-term use in pregnant women. Further studies are needed before it can be used for the duration of pregnancy. Counterintuitively, hydroxychloroquine blocks Zika by lowering the body’s ability to clear out invaders.

Footnotes